Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence.
about
Antibiotic therapy for treatment of infective endocarditisManagement of multidrug-resistant enterococcal infectionsVancomycin-associated nephrotoxicity: grave concern or death by character assassination?Inspecting the potential physiological and biomedical value of 44 conserved uncharacterised proteins of Streptococcus pneumoniaeClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Short-term success, but long-term treatment failure with linezolid for enterococcal endocarditis.Linezolid for the treatment of drug-resistant infections.Update on the safety of linezolid.In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.Enterococcal endocarditis: can we win the war?Clinical update on linezolid in the treatment of Gram-positive bacterial infections.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Linezolid for the treatment of patients with central nervous system infection.Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid.Linezolid: effectiveness and safety for approved and off-label indications.Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic wavesSwedish guidelines for diagnosis and treatment of infective endocarditis.Current challenges in treating MRSA: what are the options?Emergence and management of drug-resistant enterococcal infections.Linezolid for patients with neutropenia: are bacteriostatic agents appropriate?Infective endocarditis--prophylaxis, diagnostic criteria, and treatment.Proper use of antibiotics: situation of linezolid at the intensive care unit of the Tunisian Military Hospital.Antibacterial oxazolidinones: emerging structure-toxicity relationships.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.Tedizolid (TR-701): a new oxazolidinone with enhanced potency.An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.Enterococcal endocarditis revisited.What's New in the Treatment of Enterococcal Endocarditis?In vitro vancomycin susceptibility amongst methicillin resistant Staphylococcus aureus.Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation.Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study designGood practice in antibiotic use: what about linezolid in a French university hospital?A complicated prosthetic valve endocarditis due to methicillin resistant Staphylococci treated with linezolid and ciprofloxacin: a case report.Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: a series of 17 cases.Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis.Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.
P2860
Q24198788-C51CAB24-FA56-4947-841C-CFBE8068B0D7Q28285907-BA2E8CFB-8A1F-46BF-B0DF-06DFCB8AA34FQ33617737-1B9849FD-FFB3-4A03-BEF3-A36620811785Q34085006-667F4850-6A3D-422C-AA13-A15D855AD293Q34157657-A72D4D2E-ECF5-485A-A185-9DF91A4CCFE2Q34793549-45A92B7B-12F2-4397-8210-89CA44345A05Q34894133-E7AD166E-9E9E-4A76-9660-2C081C05C407Q34987632-03B7AE0A-3EA9-4A8B-B723-F9E1717783E6Q35191417-0F20A2A4-6872-4093-9CC4-959A1C1A214EQ35385108-7E60D164-5AD2-4B7D-BE6E-7F9D25FCC011Q35610638-6D044141-52AD-4AC4-B797-9AC4A25B1694Q36083208-C09C072D-12AE-4068-818B-3DFCC1A794C8Q36718474-A76FB320-E19C-4AB2-8ED8-B7402C58C3FEQ36729811-4EE66CB8-6070-4547-A0F3-9E2B87F69EFCQ36758570-D55324B3-3A73-4C7F-84CD-AEFA4CCCE292Q36939685-FAE62E0A-76BF-48B4-91C5-4B6EBC99B13CQ36967288-35042431-C699-45F7-97C9-84C96B0F32B2Q36999966-EC1B573D-36ED-4EF4-8143-4F68A1BC1560Q37008713-4367130E-0D3A-4210-8C0E-250F51F43E04Q37291338-F43EE0E3-F6DE-490D-A655-D752CFD6E293Q37291346-B8B48A6B-64BC-4658-93E8-EF74FD5682CAQ37463209-BFF68321-467C-4C13-A049-FC98C7598A71Q37591949-FFD74203-B236-4E06-B0CE-6203616C1789Q37666712-0C6CA923-C1A4-4536-B4B4-B83F887E52E6Q37747401-A8A8F81E-BDF0-42A0-BCBC-3BB9C9285C81Q37785546-4ADEB99C-EB08-4260-94DF-B5B2347AC635Q37869258-7335AC50-2330-44A5-B926-3DF8F86C7D43Q37983130-A88ED874-6ABC-42B8-8483-E6D6A0AC2C0AQ38070154-95CC95C6-D21B-4D14-99FD-240627E1FB09Q38539279-5D5719DA-72CE-4AFB-B646-80095E5A94E8Q41368979-BB908EF5-D1ED-4085-8C0C-F9D2DB018FC4Q41672254-9DB238BD-07DD-4E92-A7F7-BD590F5BADB8Q42272352-FBF7DF93-1253-4AF1-B36E-A2F290893543Q42544277-801986B0-11AD-47F4-9B63-4EF938CBF07AQ43490644-9B6A3869-8031-44AF-AC84-AB06DB6CABCDQ43621611-1E6CA717-376A-458F-9C89-3B811A8EF5A4Q44047004-69EB69E0-A27D-41EA-9612-9B88E218930EQ46456918-7193FD31-0CFC-4A4F-9635-05FD66B82622Q47611899-90E57B21-591F-47E3-B873-E0D170BA77D1Q47634145-994ECEB2-44DF-4028-AD76-33CC2D80EC7D
P2860
Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Linezolid for the treatment of ...... iew of the published evidence.
@ast
Linezolid for the treatment of ...... iew of the published evidence.
@en
type
label
Linezolid for the treatment of ...... iew of the published evidence.
@ast
Linezolid for the treatment of ...... iew of the published evidence.
@en
prefLabel
Linezolid for the treatment of ...... iew of the published evidence.
@ast
Linezolid for the treatment of ...... iew of the published evidence.
@en
P356
P1476
Linezolid for the treatment of ...... iew of the published evidence.
@en
P2093
Fotinie Ntziora
Katerina G Manta
P304
P356
10.1093/JAC/DKL219
P407
P577
2006-05-30T00:00:00Z